LYCOS RETRIEVER 
Disease: Patients
built 629 days ago
Patients with coronary heart disease who took Lipitor® (atorvastatin calcium) 80 mg Tablets reduced the risk of hospitalizations due to heart failure compared with those patients taking the 10 mg dose of Lipitor. Lipitor 80 mg significantly reduced the risk of hospitalizations due to heart failure for patients with heart disease by 26 percent. For those with a history of heart failure, Lipitor 80 mg significantly reduced the risk by 41 percent. This new analysis of a subset of patients from the five-year TNT (Treating to New Targets) study was published in the journal Circulation.
Source:
Mayo Clinic is recognized internationally for its excellence in treating Crohn's disease. Each year about 2,000 patients with Crohn's disease come to Mayo Clinic for care. Gastroenterologists, colorectal surgeons, radiologists and pathologists work together to diagnose and treat Crohn's disease. At Mayo Clinic, patients have access to the latest therapies and leading experts and researchers on Crohn's disease. Surgery is necessary in some cases. Mayo's colorectal surgery program is one of the largest in the world.
Source:
Scleroderma is a chronic, autoimmune disease in which normal tissue is replaced with dense, thick fibrous tissue. In patients with scleroderma, the immune system triggers other cells to produce collagen in excess quantities. This excess collagen is deposited in the skin and organs, which causes hardening and thickening (similar to the scarring process). Although it most often affects the skin, scleroderma can ... affect the gastrointestinal tract, lungs, kidneys, heart, blood vessels, muscles and joints. Scleroderma, in its most severe forms, may be life-threatening.
Source:
Many diseases are associated with accelerated bone loss, including osteoporosis, cancer, and Paget's disease. In some diseases, the rate of loss is slow and subtle, while in others the rate is rapid and acutely life- threatening. In osteoporosis, the most prevalent bone-losing condition, the process of bone loss extends over many years before the disease becomes evident. Conversely, in cancer-related hypercalcemia, bone loss is so rapid that it overwhelms the kidney's ability to eliminate calcium from the blood, and this condition can quickly become lethal. In patients with cancer-related hypercalcemia who were resistant to hydration, randomized double-blind trials have been conducted with Ganite compared with calcitonin and with two bisphosphonates (etidronate [Didronel(R); Proctor and Gamble] and pamidronate [Aredia(R); Novartis, Inc.]).
Source:
Blood transfusions help benefit sickle cell disease patients by reducing recurrent pain crises, risk of stroke and other complications. Because red blood cells contain iron, and there is no natural way for the body to eliminate it, patients who receive repeated blood transfusions can accumulate iron in the body until it reaches toxic levels. It is important to remove excess iron from the body, because it can gather in the heart, liver, and other organs and may lead to organ damage. Treatments are available to eliminate iron overload.
Source:
VIA's lead product candidate, VIA-2291, is a small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events, including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.
Source:
MORE ABOUT
Patients